Jinxin Fertility has became a leading assisted reproductive services provider in China and the United States which we have achieved through accumulating decades of experience and continue to expand our network to provide high-end services of increasing value. Its subsidiaries include Chengdu Xinan, Shenzhen Zhongshan and US-based HRC, which are three assisted reproductive technology centers.
The history of our Group can be traced back to 2003 when an experienced and dedicated team of physicians and management personnel had the vision to form Jinjiang IVF Center in Chengdu, Sichuan to focus on ARS and related treatment. Shenzhen Zhongshan Hospital was established in May 2004 by a number of individual founders (including Mr. Zeng Yong, one of the members of our senior management). Shenzhen Zhongshan Hospital provides ARS and other ancillary medical services and it assisted in the birth of the first baby, using conventional IVF-ET and IVF with ICSI technology.
The assisted reproductive medical facilities in our network in China ranked third in China’s ARS market in 2017 with 18,018 IVF treatment cycles performed, representing approximately 3.0% of total China market share, according to the F&S Report. These facilities also ranked first among China’s non-state-owned ARS providers in 2017 based on the same metric.
Through our recent acquisition of HRC Management, which manages HRC Medical, we have enhanced our capabilities to provide high-value ARS to international patients, in particular, those from China. HRC Fertility is a leading full-service ARS provider in the United States with more than 30 years of experience, providing PGS services in addition to similar IVF services we provide in China, and PGD services through third-party clinics or agencies. It ranked first among all ARS providers in the United States, in terms of IVF treatment cycles provided to ARS patients traveling from China to the United States for treatment in 2017, according to the F&S Report.